Comparative Pharmacology
Head-to-head clinical analysis: PROVOCHOLINE versus SALAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVOCHOLINE versus SALAGEN.
PROVOCHOLINE vs SALAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
Pilocarpine is a cholinergic parasympathomimetic agent that acts as a muscarinic receptor agonist, stimulating exocrine gland secretion (salivary, sweat, lacrimal, gastric, pancreatic) and smooth muscle contraction.
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
5 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may be prolonged to 6-8 hours in elderly or those with hepatic impairment.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Renal excretion of unchanged drug and metabolites: 80-90% in urine, with approximately 20% unchanged; biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist